Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir and Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B
NCT00917761Phase 4
Key facts
- Status
- Unknown
- Start
- Feb 2007
- Primary completion
- Dec 2013
- Countries
- 1
- Sponsor
- National Taiwan University Hospital
- Modality
- Small Molecules
- Drugs
- entecavir
- Conditions
- Chronic Hepatitis B (CHB)
01
Overview
Phase 4, randomised, double-blind trial of entecavir in Chronic Hepatitis B (CHB), sponsored by National Taiwan University Hospital. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for the treatment with HBeAg negative CHB, with the overall ALT normalization and HBV viral suppression far from satisfactory. Therefore, efforts on the various combinations with the currently available drugs are needed to improve the overall response rates. The simultaneous combination therapy with oral nucleoside and peginterferon alfa-2a from large-scaled randomized trials did not show a superior response rate over peginterferon alfa-2a monotherapy. Recently, sequential monotherapy with lamivudine for the first 4 weeks,…
Beyond the preview
Go deeper on NCT00917761.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00917761.